ChemGenex Pharmaceuticals Report issue

Contributed to NME For profit Phase 2
Founded: Oakland CA United States (1958)
Status: Acquired by Cephalon (2011) → now Teva (2011)

Organization Overview

First Clinical Trial
2005
NCT00114959
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

imatinib (gleevec) (1 trial)

omacetaxine (synribo) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blast Crisis (Phase 2)

Chronic Disease (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Accelerated Phase (Phase 2)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2